Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055589 | 0.94 | CA2 (0.44) | CA9CA2P2RX3MEN1KMT2A | |
| SCHEMBL3055755 | 0.89 | P2RX3 (0.47) | CA9CA2P2RX3MEN1KMT2A | |
| SCHEMBL3153291 | 0.87 | GRM5 (0.52) | CA9CA2P2RX3MEN1KMT2A | |
| SCHEMBL3052615 | 0.84 | CA9 (0.59) | CA9CA2MEN1KMT2AKDM4E | |
| SCHEMBL3186155 | 0.81 | GRM5 (0.45) | P2RX3KDM4E | |
| SCHEMBL3064371 | 0.78 | CA9 (0.76) | CA9CA2MEN1KMT2AKDM4E | |
| SCHEMBL3054937 | 0.78 | CA9 (0.54) | CA9CA2MEN1KMT2AKDM4E | |
| SCHEMBL3055432 | 0.77 | CA9 (0.61) | CA9CA2MEN1KMT2AKDM4E | |
| SCHEMBL3051083 | 0.76 | HTR2A (0.54) | — | |
| SCHEMBL3058816 | 0.75 | CA2 (0.43) | CA9CA2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | claimed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | claimed |
| EP-2155192-B1 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LTD (GB) | 2016-09-28 | — | — | EP | disclosed |
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | CA9 1002/4885CA2 1077/4885P2RX3 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.